220 related articles for article (PubMed ID: 28641031)
1. Treatment options for nonalcoholic steatohepatitis - a safety evaluation.
Issa D; Wattacheril J; Sanyal AJ
Expert Opin Drug Saf; 2017 Aug; 16(8):903-913. PubMed ID: 28641031
[TBL] [Abstract][Full Text] [Related]
2. Novel Pharmacotherapy Options for NASH.
Ratziu V
Dig Dis Sci; 2016 May; 61(5):1398-405. PubMed ID: 27003143
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
Cernea S; Cahn A; Raz I
Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
[TBL] [Abstract][Full Text] [Related]
4. NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges.
Alkhouri N
Expert Opin Investig Drugs; 2020 Feb; 29(2):87. PubMed ID: 31984804
[No Abstract] [Full Text] [Related]
5. Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis.
Verzijl CRC; Van De Peppel IP; Struik D; Jonker JW
Expert Opin Investig Drugs; 2020 Feb; 29(2):125-133. PubMed ID: 31899984
[No Abstract] [Full Text] [Related]
6. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
[No Abstract] [Full Text] [Related]
7. Promising therapies for treatment of nonalcoholic steatohepatitis.
Noureddin M; Zhang A; Loomba R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
[TBL] [Abstract][Full Text] [Related]
8. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
9. NASH: A glance at the landscape of pharmacological treatment.
Brodosi L; Marchignoli F; Petroni ML; Marchesini G
Ann Hepatol; 2016; 15(5):673-81. PubMed ID: 27493105
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy for Nonalcoholic Fatty Liver Disease.
Gawrieh S; Chalasani N
Semin Liver Dis; 2015 Aug; 35(3):338-48. PubMed ID: 26378648
[TBL] [Abstract][Full Text] [Related]
11. Anti-diabetic drugs and NASH: from current options to promising perspectives.
Smati S; Canivet CM; Boursier J; Cariou B
Expert Opin Investig Drugs; 2021 Aug; 30(8):813-825. PubMed ID: 34214406
[No Abstract] [Full Text] [Related]
12. Evolving therapies for non-alcoholic steatohepatitis.
Tilg H; Moschen AR
Expert Opin Drug Discov; 2014 Jun; 9(6):687-96. PubMed ID: 24766298
[TBL] [Abstract][Full Text] [Related]
13. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Corey KE; Rinella ME
Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
[TBL] [Abstract][Full Text] [Related]
14. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway.
Filozof C; Goldstein BJ; Williams RN; Sanyal A
Drugs; 2015 Aug; 75(12):1373-92. PubMed ID: 26201461
[TBL] [Abstract][Full Text] [Related]
15. Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease.
Sun DQ; Wu SJ; Liu WY; Lu QD; Zhu GQ; Shi KQ; Braddock M; Song D; Zheng MH
Expert Opin Ther Targets; 2016; 20(3):375-87. PubMed ID: 26419119
[TBL] [Abstract][Full Text] [Related]
16. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
Rotman Y; Sanyal AJ
Gut; 2017 Jan; 66(1):180-190. PubMed ID: 27646933
[TBL] [Abstract][Full Text] [Related]
17. Multi-drug approaches to NASH: what's in the development pipeline?
Johnston MP; Patel J; Byrne CD
Expert Opin Investig Drugs; 2020 Feb; 29(2):143-150. PubMed ID: 31524533
[No Abstract] [Full Text] [Related]
18. [Treatment Options in Non-alcoholic Fatty Liver Disease].
Kim W
Korean J Gastroenterol; 2017 Jun; 69(6):353-358. PubMed ID: 28637104
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.
Eshraghian A
World J Gastroenterol; 2017 Nov; 23(42):7495-7504. PubMed ID: 29204050
[TBL] [Abstract][Full Text] [Related]
20. Emerging and future therapies for nonalcoholic steatohepatitis in adults.
Mintziori G; Polyzos SA
Expert Opin Pharmacother; 2016 Oct; 17(14):1937-46. PubMed ID: 27564402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
